Is ketamine legal in Australia?

Ketamine is a Schedule 8 controlled drug under the Australian Poisons Standard. It is legally available only by prescription within its approved clinical indications, subject to state and territory controlled-drug permit requirements. Possession or use outside a valid prescription is a criminal offence.

How is ketamine different from psilocybin under Australian law?

They sit in different scheduling categories. Ketamine has been Schedule 8 for decades as an approved anaesthetic. Psilocybin was a Schedule 9 prohibited substance until February 2023, when the TGA allowed its use by Authorised Prescribers under a specific approval pathway — but it remains Schedule 9 (prohibited) for anyone outside that narrow framework. The two substances also act on completely different receptor systems.

Can a doctor in Australia prescribe ketamine for off-label purposes?

Yes, subject to strict regulatory requirements. Off-label or investigational use may be accessed through the TGA's Special Access Scheme (SAS Category B) or the Authorised Prescriber pathway, both of which require formal TGA documentation, clinical justification, and ongoing oversight. These are not casual mechanisms — they involve significant regulatory oversight.

What are the known harms of ketamine misuse?

The Australian Drug Foundation documents that non-clinical ketamine use is associated with bladder and urinary tract damage (which can be severe and irreversible with chronic use), psychological dependence, impaired motor function, and dangerous states of profound dissociation. These risks are well-documented in the harm-reduction and clinical literature and are part of the rationale for its Schedule 8 classification.

Does research on ketamine mean it is safe to use without medical supervision?

No. Published research describes observed effects and proposed mechanisms in controlled, supervised study conditions. It does not constitute a recommendation for unsupervised use. Regulatory approval of any medicine requires extensive safety and efficacy review beyond individual studies, and ketamine's Schedule 8 status reflects a documented risk profile that includes misuse potential and serious adverse effects.

Ketamine in Medicine: Regulatory and Clinical Context

By Daniel Okoro · 28 June 2026 · 7 min read

brown and white mushroom in close up photography

Ketamine's scheduling position in Australia

Roughly 180 countries have ketamine on their essential medicines lists. That number always surprises people , because in popular conversation it gets lumped together with newer psychedelic-assisted approaches, which sit in a very different regulatory category. Ketamine is not psilocybin. The distinction matters legally, and I want to be precise about it from the outset.

In Australia, ketamine is a Schedule 8 controlled drug under the Poisons Standard (the document the TGA maintains to classify substances by risk and access). Schedule 8 means it requires a prescription, is subject to state and territory controlled-drug permit requirements, and sits under tighter dispensing and record-keeping obligations than ordinary prescription medicines. It is emphatically not a freely available substance. Unauthorised possession or supply carries serious criminal penalties under state law.

For comparison: psilocybin was a Schedule 9 prohibited substance until February 2023, when the TGA's rescheduling decision allowed it to be prescribed as a Schedule 8 drug , but only by Authorised Prescribers under a specific TGA approval pathway. Ketamine did not go through that same rescheduling event; it has been Schedule 8 for decades and is already an approved anaesthetic agent with a long clinical history. The research interest in its dissociative properties is newer, but the compound's legal status is well-established.

What ketamine actually is, chemically

Ketamine (chemical name: (RS)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one) is an arylcyclohexylamine, synthesised in the early 1960s. Its primary mechanism is non-competitive antagonism of the NMDA (N-methyl-D-aspartate) receptor, which is a subtype of the ionotropic glutamate receptor family. This is distinct from the serotonergic pathways that classical psychedelics like psilocybin act on, and it is also distinct from the endocannabinoid system that plant-based cannabinoids interact with.

At sub-anaesthetic doses, ketamine produces dissociative states , altered perception of self and environment, sometimes described as a detachment from ordinary sensory experience. At anaesthetic doses, it induces a cataleptic state while maintaining airway reflexes and cardiovascular function, which is part of why it became widely used in emergency and field medicine. The pharmacokinetics are well-characterised: it is highly lipophilic, crosses the blood-brain barrier rapidly, and has a relatively short duration of action compared to many anaesthetics.

There are two enantiomers; S-ketamine and R-ketamine, with differing receptor affinities. Esketamine (the S-enantiomer) has received regulatory approval in some jurisdictions as an intranasal formulation for specific clinical indications. In Australia, any such use falls under TGA and ARTG approval processes; the ARTG (Australian Register of Therapeutic Goods) is the gating mechanism for whether a product can be lawfully supplied here.

How it reaches patients legally in Australia

The clearest legal pathway for ketamine in Australian clinical settings runs through its established use as an anaesthetic agent, where it appears in approved formulations on the ARTG. Prescription access is governed by the Poisons Standard and state/territory controlled-drug legislation. In practice, this means a registered medical practitioner can prescribe it within approved indications, with all the documentation that Schedule 8 requires.

Where things get more layered is in off-label or investigational use. The TGA's Special Access Scheme (SAS) and the Authorised Prescriber pathway exist for situations where a clinician wants to use a medicine outside its approved indications, or where a medicine has not been fully approved for a specific use in Australia. SAS Category B allows individual patient access to unapproved goods when a registered medical practitioner determines it is clinically necessary. These are not workarounds, they are formal regulatory mechanisms with documented oversight.

I'll be direct: if someone is asking how to access ketamine outside a clinical setting, that is a question with a straightforward legal answer. Possession or use without a valid prescription is a criminal offence. No educational framing changes that.

The research landscape; and its limits

The body of published research on ketamine is genuinely substantial. A 2019 meta-analysis published in Psychopharmacology (Fond et al.) examined randomised controlled trial data and reported on the compound's rapid-onset effects in controlled study conditions. A 2023 review in Nature Mental Health looked at mechanistic hypotheses, discussing NMDA antagonism, downstream glutamatergic signalling, and AMPA receptor upregulation as potential contributors to the observed effects in study participants.

I read through a stack of these papers last year, this was around the time I was also trying to learn a Monk piece on the piano and failing at both simultaneously, and one thing that struck me was how careful the methodology sections were about controlling for dissociation as a confounder. That is, some researchers have raised legitimate questions about whether blinding is truly achievable in ketamine trials, since participants can often tell whether they received the active compound. It's a real methodological challenge that the field is still grappling with honestly.

None of that research, including this article, constitutes evidence that ketamine treats, cures, or manages any condition. The research describes observed associations and proposed mechanisms in controlled study contexts. Regulatory approval, where it exists, is granted on the basis of much more extensive safety and efficacy review than any single study provides.

Misuse, dependence, and harms

The ADF (Australian Drug Foundation) documents ketamine misuse clearly. In non-clinical settings, the drug has been used recreationally, sometimes in combinations that carry serious risks. High-dose or chronic use has been associated with bladder and urinary tract damage; sometimes severe and irreversible, and with psychological dependence. These are not rare edge-case outcomes; they appear consistently in the harm-reduction and clinical literature.

Ketamine's dissociative effects can impair judgement, motor function, and the ability to respond to environmental hazards. The "k-hole", a term in recreational-use accounts for a state of profound dissociation; describes an experience that can include immobility and unresponsiveness, which is dangerous outside a medically controlled environment by any honest assessment.

The TGA's scheduling of ketamine as a controlled drug reflects this risk profile. Schedule 8 controls exist not as bureaucratic formality but because the abuse potential and harm potential of these compounds is real and documented.

Ketamine versus the broader psychedelic rescheduling context

Since the TGA's February 2023 decision to reschedule psilocybin and MDMA to Schedule 8 for use by Authorised Prescribers, there has been increased public interest in what I'd loosely call the "dissociative and psychedelic" cluster of compounds. It's worth separating these carefully.

MDMA and psilocybin accessed outside the Authorised Prescriber pathway remain Schedule 9 prohibited substances. Possession is a criminal offence. The Authorised Prescriber mechanism is narrow, it requires TGA approval of the individual prescriber, a specific approved indication, and clinical oversight. It is not a general legalisation.

Ketamine's situation is different in that it has a long history as an approved medicine. But the interest in its dissociative properties for investigational purposes does not change the fundamental access rules. If anything, the increased research profile has prompted closer regulatory attention, not relaxation.

My honest view: the policy conversation around psychedelic-adjacent compounds in Australia has moved faster than public education about what the regulatory frameworks actually require. That gap creates real risk, people hear "approved" and assume it means widely available. It doesn't. The Authorised Prescriber and SAS pathways are deliberately narrow for reasons that include genuine safety considerations.

Key regulatory frameworks to know

For anyone trying to understand this space properly, the primary documents are:

The Poisons Standard (the SUSMP), maintained by the TGA; this is the operative scheduling document.
The TGA's Authorised Prescriber and Special Access Scheme guidance, available at tga.gov.au.
State and territory controlled-drug legislation, which varies and applies on top of the federal scheduling framework.
The Good Manufacturing Practice standards that govern how any TGA-listed product is manufactured, which apply to ketamine formulations as with any other medicine.

The bioavailability of different ketamine formulations (intravenous, intramuscular, intranasal, oral) varies substantially and is a pharmacological consideration within clinical use, but formulation decisions belong entirely within the clinical domain, under the oversight of qualified prescribers.

Sources

, Daniel Okoro, Psychedelic science & law writer

Common questions

Is ketamine legal in Australia?: Ketamine is a Schedule 8 controlled drug under the Australian Poisons Standard. It is legally available only by prescription within its approved clinical indications, subject to state and territory controlled-drug permit requirements. Possession or use outside a valid prescription is a criminal offence.
How is ketamine different from psilocybin under Australian law?: They sit in different scheduling categories. Ketamine has been Schedule 8 for decades as an approved anaesthetic. Psilocybin was a Schedule 9 prohibited substance until February 2023, when the TGA allowed its use by Authorised Prescribers under a specific approval pathway — but it remains Schedule 9 (prohibited) for anyone outside that narrow framework. The two substances also act on completely different receptor systems.
Can a doctor in Australia prescribe ketamine for off-label purposes?: Yes, subject to strict regulatory requirements. Off-label or investigational use may be accessed through the TGA's Special Access Scheme (SAS Category B) or the Authorised Prescriber pathway, both of which require formal TGA documentation, clinical justification, and ongoing oversight. These are not casual mechanisms — they involve significant regulatory oversight.
What are the known harms of ketamine misuse?: The Australian Drug Foundation documents that non-clinical ketamine use is associated with bladder and urinary tract damage (which can be severe and irreversible with chronic use), psychological dependence, impaired motor function, and dangerous states of profound dissociation. These risks are well-documented in the harm-reduction and clinical literature and are part of the rationale for its Schedule 8 classification.
Does research on ketamine mean it is safe to use without medical supervision?: No. Published research describes observed effects and proposed mechanisms in controlled, supervised study conditions. It does not constitute a recommendation for unsupervised use. Regulatory approval of any medicine requires extensive safety and efficacy review beyond individual studies, and ketamine's Schedule 8 status reflects a documented risk profile that includes misuse potential and serious adverse effects.